Hemoglobin, erythropoietin and systemic inflammation in exacerbations of chronic obstructive pulmonary disease.
Détails
ID Serval
serval:BIB_CA578268D853
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Hemoglobin, erythropoietin and systemic inflammation in exacerbations of chronic obstructive pulmonary disease.
Périodique
European journal of internal medicine
ISSN
1879-0828 (Electronic)
ISSN-L
0953-6205
Statut éditorial
Publié
Date de publication
02/2011
Peer-reviewed
Oui
Volume
22
Numéro
1
Pages
103-107
Langue
anglais
Notes
Publication types: Comparative Study ; Journal Article ; Research Support, Non-U.S. Gov't
Publication Status: ppublish
Publication Status: ppublish
Résumé
Systemic inflammation may represent a possible cause of anemia. Previous data support that anemic patients with COPD present high erythropoietin (EPO) levels, suggestive of EPO resistance, possibly mediated through inflammatory mechanisms.
We aimed to determine whether systemic inflammation, which is usually up-regulated during exacerbations of COPD (ECOPD) is associated with low hemoglobin levels expressing erythropoietin resistance.
Hemoglobin (Hb), EPO and serum biomarkers of systemic inflammation [CRP, TNF-α, fibrinogen and IL-6] were assessed at three time points (admission, resolution and stable phases) in a selected cohort of 93 COPD patients.
Hemoglobin levels were significantly lower on admission compared to resolution and stable phases (median 12.1 g/dl [interquartile ranges 11.2-12.7], vs 13.5 [12.4-14.3] vs 13.4 [12.7-14.08], respectively p=0.002), whereas EPO was significantly higher on admission compared to resolution and stable phases. A negative association between Hb and IL-6 and a positive association between EPO and IL-6 were observed only during the acute phase of exacerbation. EPO and Hb were negatively associated during the acute phase, whereas they were positively associated during discharge and stable phase.
In this observational study we have shown that during admission for ECOPD Hb levels are decreased and EPO levels are increased. We have also identified a negative association between Hb and EPO. The above association is mainly related to increased IL-6 levels, indicating a possible EPO resistance through the mechanism of increased systemic inflammatory process.
We aimed to determine whether systemic inflammation, which is usually up-regulated during exacerbations of COPD (ECOPD) is associated with low hemoglobin levels expressing erythropoietin resistance.
Hemoglobin (Hb), EPO and serum biomarkers of systemic inflammation [CRP, TNF-α, fibrinogen and IL-6] were assessed at three time points (admission, resolution and stable phases) in a selected cohort of 93 COPD patients.
Hemoglobin levels were significantly lower on admission compared to resolution and stable phases (median 12.1 g/dl [interquartile ranges 11.2-12.7], vs 13.5 [12.4-14.3] vs 13.4 [12.7-14.08], respectively p=0.002), whereas EPO was significantly higher on admission compared to resolution and stable phases. A negative association between Hb and IL-6 and a positive association between EPO and IL-6 were observed only during the acute phase of exacerbation. EPO and Hb were negatively associated during the acute phase, whereas they were positively associated during discharge and stable phase.
In this observational study we have shown that during admission for ECOPD Hb levels are decreased and EPO levels are increased. We have also identified a negative association between Hb and EPO. The above association is mainly related to increased IL-6 levels, indicating a possible EPO resistance through the mechanism of increased systemic inflammatory process.
Mots-clé
Aged, Biomarkers/blood, Cohort Studies, Erythropoietin/blood, Female, Hemoglobins/metabolism, Humans, Inflammation/blood, Inflammation/complications, Interleukin-6/blood, Male, Middle Aged, Pulmonary Disease, Chronic Obstructive/blood, Pulmonary Disease, Chronic Obstructive/complications, Recurrence, Risk Assessment, Risk Factors, Tumor Necrosis Factor-alpha/blood
Pubmed
Web of science
Création de la notice
19/07/2019 18:36
Dernière modification de la notice
21/08/2019 5:32